CHESTER C. WOOD, M.D.; ALAN E. WILLIAMS, Ph.D.; JAMES G. McNAMARA, M.D.; JOSEPHINE A. ANNUNZIATA, B.S.; PAUL M. FEORINO, Ph.D.; CHRISTOPHER O. CONWAY, M.S.
In a 6-month study, antibody levels against the human immunodeficiency virus (HIV) were determined in intravenous gammaglobulin preparations and 45 serum samples from 20 patients on gammaglobulin therapy. All 10 lots of a reduced and alkylated preparation and 4 of 8 lots of a pH4/pepsin-treated preparation were seropositive by enzyme-linked immunosorbent assay (ELISA). By Western blot analysis, 8 of 10 lots of the reduced and alkylated preparation and 3 of 8 lots of the pH4/pepsin-treated preparation were positive. Before gammaglobulin infusion, 2 of 45 preinfusion samples were seropositive by ELISA but seronegative by Western blot. After infusion, 15 of 45 samples were seropositive by ELISA, and 8 had antibody against p24 by Western blot. Seropositivity persisted for less than 1 month. Cultures of HIV-positive intravenous gammaglobulin lots were negative for reverse transcriptase activity or viral antigen expression. These results suggest that current methods of preparation either exclude or inactivate HIV.
CHESTER C. WOOD, ALAN E. WILLIAMS, JAMES G. McNAMARA, JOSEPHINE A. ANNUNZIATA, PAUL M. FEORINO, CHRISTOPHER O. CONWAY. Antibody Against the Human Immunodeficiency Virus in Commercial Intravenous Gammaglobulin Preparations. Ann Intern Med. 1986;105:536–538. doi: 10.7326/0003-4819-105-4-536
Download citation file:
Published: Ann Intern Med. 1986;105(4):536-538.
HIV, Infectious Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use